Table 5. Adverse events and switch of immunosuppression.
| Control (n = 86) | BKV (n = 86) | |
|---|---|---|
| Loss of function | 4 | 4 |
| Acute rejection | 1 | 3 |
| HUS recurrence | 1 | − |
| BKN and acute rejection | − | 1 |
| Chronic transplantat nephropathy | 2 | − |
| Switch from Tac to other IS | 22/79 | 37/75 |
| Everolimus | 7 | 13 |
| Tacrolimus extended release (Advagraf) | 3 | 1 |
| Cyclosporin A | 6 | 20 |
| Sirolimus | 6 | 2 |
| Tac termination without replacement | − | 1 |
| Cause of switch from Tac | ||
| BKV infection | − | 20 |
| Malignoma | 4 | 1 |
| Alopecia | − | − |
| Tac blood level fluctuations | 1 | 1 |
| Bacterial infection | 2 | − |
| CMV infection | − | 1 |
| CNI nephrotoxicity | 6 | 6 |
| Diabetes mellitus | 6 | 5 |
| Incompliance | 1 | − |
| Neurotoxicity | 1 | 3 |
| HUS | 1 | − |
Frequencies of adverse events and switch from Tac during the 4 year follow-up. Abbreviations: BKV, BK virus; Tac, tacrolimus twice daily; IS, immunosuppression; HUS, hemolytic uremic syndrome; BKN, BKV-associated nephropathy.